CABA
Cabaletta Bio, Inc. NASDAQ Listed Oct 25, 2019$3.98
Mkt Cap $382.7M
52w Low $1.11
91.8% of range
52w High $4.23
50d MA $3.13
200d MA $2.47
P/E (TTM)
-1.8x
EV/EBITDA
-1.0x
P/B
2.7x
Debt/Equity
0.2x
ROE
-149.8%
P/FCF
-1.7x
RSI (14)
—
ATR (14)
—
Beta
3.29
50d MA
$3.13
200d MA
$2.47
Avg Volume
2.4M
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
2929 Arch Street · Philadelphia, PA 19104 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -0.45 | -0.40 | +11.1% | 2.82 | -2.1% | -5.3% | +4.1% | +1.4% | -5.0% | -7.8% | — |
| Nov 10, 2025 | AMC | -0.49 | -0.44 | +10.2% | 2.43 | +0.8% | +1.6% | -0.8% | -4.5% | -1.3% | +3.5% | — |
| Aug 7, 2025 | AMC | -0.71 | -0.73 | -2.8% | 1.45 | +0.0% | -6.2% | -2.2% | +0.0% | +28.6% | -3.5% | — |
| May 15, 2025 | AMC | -0.67 | -0.71 | -6.0% | 1.81 | +18.2% | +12.2% | -5.4% | -2.1% | -4.3% | -1.1% | — |
| Mar 31, 2025 | AMC | -0.65 | -0.65 | +0.0% | 1.39 | +0.0% | -15.8% | +6.0% | -4.0% | -6.7% | +3.6% | — |
| Nov 14, 2024 | AMC | -0.59 | -0.62 | -5.1% | 3.78 | +1.6% | -19.8% | -10.9% | -5.9% | -11.0% | -17.3% | — |
| Aug 8, 2024 | AMC | -0.55 | -0.56 | -1.8% | 4.01 | +0.7% | +3.7% | +5.3% | +4.1% | -3.9% | +1.8% | — |
| May 15, 2024 | AMC | -0.48 | -0.51 | -6.2% | 12.69 | -1.3% | -0.6% | -2.1% | +4.3% | -5.4% | -3.1% | — |
| Mar 21, 2024 | AMC | -0.39 | -0.46 | -17.9% | 17.54 | -3.6% | -1.1% | -3.2% | +1.0% | +1.1% | -0.5% | — |
| Nov 9, 2023 | AMC | -0.39 | -0.37 | +5.1% | 17.52 | +4.2% | +2.1% | -2.6% | +0.3% | -0.6% | +0.4% | — |
| Aug 10, 2023 | AMC | -0.47 | -0.37 | +21.3% | 12.27 | +2.2% | +11.0% | -1.4% | +1.8% | -4.2% | -6.9% | — |
| May 11, 2023 | AMC | -0.48 | -0.45 | +6.2% | 13.12 | -0.1% | -4.7% | -8.2% | +14.6% | -7.8% | +1.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $2.82 | $2.76 | -2.1% | -5.3% | +4.1% | +1.4% | -5.0% | -7.8% |
| Mar 24 | Guggenheim | Maintains | Buy → Buy | — | $2.82 | $2.76 | -2.1% | -5.3% | +4.1% | +1.4% | -5.0% | -7.8% |
| Oct 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.47 | $2.61 | +5.7% | +46.2% | -16.6% | -10.3% | -3.3% | -5.0% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.85 | $3.15 | +10.5% | -18.6% | +7.3% | +16.1% | +0.3% | -0.7% |
| Sep 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.54 | $1.57 | +1.9% | +10.4% | -1.2% | -2.4% | +6.1% | +4.0% |
| Aug 14 | Citigroup | Maintains | Buy → Buy | — | $1.71 | $1.67 | -2.3% | -3.5% | +3.6% | +3.5% | -8.5% | -2.5% |
| Aug 8 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $1.45 | $1.45 | +0.0% | -6.2% | -2.2% | +0.0% | +28.6% | -3.5% |
| Aug 8 | Guggenheim | Maintains | Buy → Buy | — | $1.45 | $1.45 | +0.0% | -6.2% | -2.2% | +0.0% | +28.6% | -3.5% |
| Jun 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.35 | $2.03 | -13.6% | -25.5% | +2.9% | +10.6% | -2.5% | -3.6% |
| May 16 | Citigroup | Maintains | Buy → Buy | — | $1.81 | $2.14 | +18.2% | +12.2% | -5.4% | -2.1% | -4.3% | -1.1% |
| May 16 | Guggenheim | Maintains | Buy → Buy | — | $1.81 | $2.14 | +18.2% | +12.2% | -5.4% | -2.1% | -4.3% | -1.1% |
| May 15 | Guggenheim | Maintains | Buy → Buy | — | $1.30 | $1.40 | +7.7% | +39.2% | +12.2% | -5.4% | -2.1% | -4.3% |
| Apr 1 | UBS | Maintains | Buy → Buy | — | $1.39 | $1.39 | +0.0% | -15.8% | +6.0% | -4.0% | -6.7% | +3.6% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.39 | $1.39 | +0.0% | -15.8% | +6.0% | -4.0% | -6.7% | +3.6% |
| Apr 1 | Morgan Stanley | Maintains | Overweight → Overweight | — | $1.39 | $1.39 | +0.0% | -15.8% | +6.0% | -4.0% | -6.7% | +3.6% |
| Apr 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $1.39 | $1.39 | +0.0% | -15.8% | +6.0% | -4.0% | -6.7% | +3.6% |
| Apr 1 | Guggenheim | Maintains | Buy → Buy | — | $1.39 | $1.39 | +0.0% | -15.8% | +6.0% | -4.0% | -6.7% | +3.6% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.71 | $2.74 | +1.1% | -14.0% | -7.7% | -2.8% | -1.4% | -4.9% |
| Jan 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.43 | $2.45 | +0.8% | +12.8% | -5.1% | -2.3% | +2.0% | -3.5% |
| Dec 20 | Evercore ISI | Downgrade | Outperform → In Line | — | $2.31 | $2.27 | -1.7% | +3.0% | -0.8% | -0.8% | +6.4% | -8.0% |
| Dec 19 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $2.29 | $2.26 | -1.3% | +0.9% | +3.0% | -0.8% | -0.8% | +6.4% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.03 | $3.00 | -1.0% | -10.9% | -5.9% | -11.0% | -17.3% | +0.0% |
| Nov 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $3.78 | $3.84 | +1.6% | -19.8% | -10.9% | -5.9% | -11.0% | -17.3% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.78 | $3.84 | +1.6% | -19.8% | -10.9% | -5.9% | -11.0% | -17.3% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.94 | $4.00 | +1.5% | +6.3% | +6.9% | +4.9% | +0.0% | -7.0% |
| Aug 12 | Evercore ISI | Maintains | Outperform → Outperform | — | $4.16 | $4.26 | +2.4% | +5.3% | +4.1% | -3.9% | +1.8% | +1.8% |
| Aug 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $4.16 | $4.26 | +2.4% | +5.3% | +4.1% | -3.9% | +1.8% | +1.8% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.01 | $4.04 | +0.7% | +3.7% | +5.3% | +4.1% | -3.9% | +1.8% |
| Jun 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.33 | $8.50 | +2.0% | +1.8% | -1.5% | -13.4% | +0.4% | +1.1% |
| Jun 17 | Stifel | Maintains | Buy → Buy | — | $10.66 | $10.54 | -1.1% | -12.2% | -10.8% | -0.2% | +1.8% | -1.5% |
| Jun 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.56 | $13.35 | +6.3% | -15.1% | -12.2% | -10.8% | -0.2% | +1.8% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.21 | $11.30 | +0.8% | -2.6% | -2.3% | -5.8% | -1.2% | +2.6% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.69 | $12.52 | -1.3% | -0.6% | -2.1% | +4.3% | -5.4% | -3.1% |
| Apr 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $16.11 | $15.95 | -1.0% | +5.4% | +6.2% | +4.3% | -5.1% | +0.3% |
| Apr 4 | Citigroup | Maintains | Buy → Buy | — | $16.44 | $16.79 | +2.1% | -2.0% | +5.4% | +6.2% | +4.3% | -5.1% |
| Mar 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $17.54 | $16.91 | -3.6% | -1.1% | -3.2% | +1.0% | +1.1% | -0.5% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.54 | $16.91 | -3.6% | -1.1% | -3.2% | +1.0% | +1.1% | -0.5% |
| Mar 22 | Wells Fargo | Maintains | Overweight → Overweight | — | $17.54 | $16.91 | -3.6% | -1.1% | -3.2% | +1.0% | +1.1% | -0.5% |
| Nov 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.69 | $13.60 | -0.7% | +1.4% | +15.6% | -0.2% | +0.2% | -2.7% |
| Nov 29 | Morgan Stanley | Maintains | Overweight → Overweight | — | $13.69 | $13.60 | -0.7% | +1.4% | +15.6% | -0.2% | +0.2% | -2.7% |
| Nov 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $17.47 | $18.02 | +3.1% | -0.6% | +0.4% | +3.0% | -0.1% | -1.8% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.52 | $18.25 | +4.2% | +2.1% | -2.6% | +0.3% | -0.6% | +0.4% |
| Nov 8 | Morgan Stanley | Maintains | Overweight → Overweight | — | $16.09 | $16.47 | +2.4% | +6.8% | +1.9% | +2.1% | -2.6% | +0.3% |
| Oct 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.80 | $14.58 | -1.5% | -0.2% | -2.4% | +8.3% | +5.7% | +0.0% |
| Sep 18 | Wells Fargo | Maintains | Overweight → Overweight | — | $15.81 | $16.17 | +2.3% | +18.0% | -6.9% | -7.7% | +0.1% | -1.4% |
| Aug 14 | Guggenheim | Maintains | Buy → Buy | — | $13.62 | $13.66 | +0.3% | -1.4% | +1.8% | -4.2% | -6.9% | +3.9% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.27 | $12.54 | +2.2% | +11.0% | -1.4% | +1.8% | -4.2% | -6.9% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.16 | $13.10 | -0.5% | -7.8% | +1.4% | -5.4% | -3.0% | -4.6% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.12 | $13.11 | -0.1% | -4.7% | -8.2% | +14.6% | -7.8% | +1.4% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.58 | $11.45 | -1.1% | +5.7% | -0.2% | +3.0% | -7.0% | +1.6% |
No insider trades available.
8-K · 2.02
!! High
Cabaletta Bio, Inc. -- 8-K 2.02: Earnings Results
Cabaletta Bio maintains a strong cash position of $117 million as of March 31, 2026, providing runway for clinical development and operations.
May 4
8-K · 8.01
!! High
Cabaletta Bio, Inc. -- 8-K 8.01: Material Event / Announcement
Cabaletta Bio will present positive early data from its RESET-PV trial at ASGCT 2026, demonstrating rese-cel efficacy in pemphigus vulgaris patients without requiring chemotherapy preconditioning, potentially simplifying treatment.
May 4
8-K · 8.01
!! High
Cabaletta Bio, Inc. -- 8-K 8.01: Material Event / Announcement
Cabaletta Bio filed a corporate presentation as a material event, likely signaling updates on its pipeline or strategy that investors should review for potential operational or development changes.
Apr 20
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Cabaletta Bio is progressing late-stage cell therapy candidates for autoimmune diseases, suggesting potential near-term catalyst events that could significantly impact valuation if clinical trials succeed.
Mar 23
Data updated apr 24, 2026 11:35pm
· Source: massive.com